Sanaria is a biotechnology company developing vaccines protective against malaria. Sanaria’s vaccines have proven highly protective against Plasmodium falciparum infection in humans. Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria Inc.'s blog
Sanaria® PfSPZ-CVac vaccine protected 100% of six subjects against a genetically distant variant parasite strain for 3 months, the first time that such complete protection has ever been achieved for such a long period. Results set the scene for development of a traveler’s vaccine, seasonal malaria vaccinations and genetically attenuated parasites that do not fully develop in the liver through to early blood stage.
Findings published in Nature offer potential for use by travelers and prevention of malaria in African populations in near future
ROCKVILLE, MD, USA – June 30, 2021 – Researchers from Sanaria® Inc. and the National Institutes of Health (NIH) are making progress in the development of highly protective malaria vaccines.
In an article published today in Nature, Sanaria’s PfSPZ-CVac (CQ) vaccine is reported as being safe and protecting 100% of six subjects against a variant malaria parasite three months after their last dose in the company’s Phase 1 safety and efficacy trial. This is the first time complete protection against a variant malaria parasite has ever been achieved that long after vaccine administration.
ROCKVILLE, MD, USA - June 8, 2021 - The PfSPZ malaria vaccines of Sanaria Inc. are unique in vaccine development as they are composed of weakened (attenuated) forms of the live parasite cells that cause malaria. These parasite cells are called eukaryotic cells and there are no vaccines against any infectious disease composed of such cells. Furthermore, there are no licensed vaccines against any infectious disease caused by a eukaryotic pathogen.
Watch below the recording of the MasterClass "The Enduring Search for Malaria Vaccines" with Sanaria's Chief Executive and Scientific Officer Prof Stephen Hoffman.
Ifakara MasterClasses in Public Health Research & Practice. Episode XXV: Thursday, June 3rd 2021.